User login
Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.
Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).
Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.
Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.
Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.
Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.
Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).
Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.
Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.
Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.
Key clinical point: The prevalence of low lean mass and sarcopenic obesity was significantly higher in patients with rheumatoid arthritis (RA) than the general reference population.
Major finding: Patients with RA compared to reference populations from NHANES and HealthABC had a greater prevalence of low lean mass (14.2% vs. 10.0% and 7.0%, respectively; all P < .001) and sarcopenic obesity (12.6% vs. 4.5% and 4.0%, respectively; all P < .001), with both associated with worse Health Assessment Questionnaire scores, suggesting worse disability (P < .001).
Study details: The findings came from the analysis of 113, 190, and 141 patients with RA from the University of Pennsylvania, Events in RA study, and University of San Francisco cohorts, respectively, compared with reference populations from NHANES and HealthABC.
Disclosures: This work was supported by a VA Clinical Science Research and Development Award, the National Institutes of Health, the University of Pennsylvania Clinical and Translational Research Center, among others. JF Bater declared receiving consulting fees from Bristol Myers Squibb, Gilead, and Pfizer.
Source: Baker JF et al. Rheumatology (Oxford). 2021 Sep 24. doi: 10.1093/rheumatology/keab710.